The generally high incidence of CDKN2A, CDKN2B, BRAF and FGFR2 deletion in the entire GBM patient population in previous GBM literature studies (Brennan et al., 2013; Jovčevska, 2018; Le Rhun et al., 2019; Senhaji et al., 2022) is consistent with our findings. This evidence concerns the gene FGFR2 and glioblastoma.